Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, Matthias Stelljes et autres
Background Patients with relapsed or refractory acute myeloid leukaemia have a poor prognosis. Outcomes with conventional intensive salvage chemotherapy are suboptimal. We aimed to evaluate the safety and activity of high-dose cytarabine and mitoxantrone in combination with venetoclax in patients with relapsed …
de (code pays fourni par la source)
1 citation
The Lancet Haematology